Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
“While our results are promising, a key limitation to this approach is that approximately 60 percent of patients still did not respond."
A study of melanoma patients found that treatment every six weeks is comparable to every three weeks.
“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
Immunotherapy may prolong survival compared with standard chemotherapy.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
New site-agnostic therapies highlight the importance of genetic testing.
The investigational machine has an 85% accuracy rate.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
Keytruda plus Lenvima is first approval under Project Orbis collaboration.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.